Barbara Izzo

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 512 citations · Full text

Medicine, Hematology, Oncology +15

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Daniela Cilloni, Aline Renneville, Fabienne Hermitte et al. · Journal of Clinical Oncology · 2009 · 434 citations · Full text

Medicine, Hematology, Oncology +17

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Giovanni Martinelli, Gianantonio Rosti et al. · Journal of Clinical Oncology · 2005 · 372 citations · Full text

Medicine, Hematology, Pharmacology +14

Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia

Michele Baccarani, Giovanni Martinelli, Gianantonio Rosti et al. · Blood · 2004 · 106 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +10

Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

Ilaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti et al. · Clinical Cancer Research · 2006 · 95 citations · Full text

Life Sciences, Hematology, Oncology +13